Paul Hamlin

16PUBLICATIONS
78CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Oct 02, 2026
Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.

|Jul 10, 2026
Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma.

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Feb 08, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye

|Jan 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.

Kurt S Bantilan, Alexandra N Smith, Matthew J Maurer

|Jun 12, 2023
Retrospective characterization of nodal marginal zone lymphoma.

Robert Stuver, Esther Drill, David Qualls

Pageof 3

Frequent Collaborators

10 joint publications

Gilles Salles

9 joint publications

Andrew D Zelenetz

7 joint publications

Ariela Noy

6 joint publications

Matthew Matasar